In the Phase III GIMEMA ALL2820 trial, presented at ASH, 94 percent of patients who received the chemo-free regimen had a ...

In the most recent data presented at the meeting, the CAR T-cell therapy demonstrated a 96 percent overall response rate.

At the meeting, researchers shared real-world data showing ctDNA positivity at the end of treatment was prognostic across lymphoma subtypes and better than PET scans.